Sponsor of the Day:
Jerkmate
https://www.globenewswire.com/news-release/2026/04/27/3282051/0/fr/Cellectis-pr%C3%A9sente-sa-plateforme-d-%C3%A9dition-%C3%A9pig%C3%A9n%C3%A9tique-pour-%C3%A9teindre-des-g%C3%A8nes-sans-modifier-l-ADN-lors-du-congr%C3%A8s-annuel-de-l-ASGCT.html
Cellectis présente sa plateforme d’édition épigénétique
Apr 27, 2026 - NEW YORK, 27 avr. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de biotechnologie de stade clinique, qui utilise...
sa plateformecellectis
https://www.cellectis.com/en/research/pulseagile/
PulseAgile | Cellectis
Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer.
cellectis
https://www.globenewswire.com/news-release/2026/04/27/3282051/0/en/Cellectis-Presents-Epigenetic-Editing-Platform-to-Turn-Genes-Off-Without-Altering-DNA-at-the-ASGCT-Annual-Meeting.html
Cellectis Presents Epigenetic Editing Platform to Turn
Apr 27, 2026 - NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company...
editing platformcellectispresentsepigeneticturn
https://www.cellectis.com/
Home | Cellectis
Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer
cellectis
https://www.cellectis.com/en/press/
Press | Cellectis
Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer.
presscellectis
https://www.cellectis.com/en/press/cellectis-reports-financial-results-for-the-first-quarter-2025/
Cellectis Reports Financial Results for the First Quarter 2025 | Cellectis
Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer.
reports financial resultsfirst quarter 2025cellectis